Results 21 to 30 of about 912 (125)

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Frontiers in Medicine, 2022
The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg ...
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani   +13 more
doaj   +1 more source

Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

International Journal of Endocrinology, 2014
New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to ...
Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy   +2 more
doaj   +1 more source

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Frontiers in Pharmacology, 2018
Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture.Methods: The sitagliptin cohort included 1,578 ...
Shih-Yi Lin, Shih-Yi Lin, Wu-Huei Hsu, Wu-Huei Hsu, Cheng-Chieh Lin, Cheng-Chieh Lin, Cheng-Li Lin, Cheng-Li Lin, Chun-Hao Tsai, Chun-Hao Tsai, Hung-Chieh Yeh, Chung-Y. Hsu, Chia-Hung Kao, Chia-Hung Kao, Chia-Hung Kao   +14 more
doaj   +1 more source

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia

Journal of Diabetes Investigation, 2019
Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus, with a focus on hypoglycemia.
Masahiro Fukuda, Kunihiro Doi, Masahiro Sugawara, Koichi Mochizuki   +3 more
doaj   +1 more source

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)

Endocrine Connections, 2017
Objective: To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study).
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, Sunitha Jothydev   +4 more
doaj   +1 more source

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundTo evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period.MethodsOur study design involved the addition of 100 mg sitagliptin once ...
Hye Soo Chung, Moon-Kyu Lee
doaj   +1 more source

Anomeric Amide Enabled Divergent Synthesis of Unsymmetrical Ureas, Carbamates, Thioesters, and Amides From Aldehydes

Angewandte Chemie International Edition, EarlyView.
An anomeric amide‐enabled divergent aldehyde functionalization sequence provides one‐pot access to unsymmetrical ureas, carbamates, thiocarbamates, thioesters, and amides. Key to this transformation is the formation of N‐Boc‐hydroxamate intermediates, which serve as platforms for orthogonal activation via Lossen‐type rearrangements, single‐electron ...
Jasper L. Tyler, Meiyi Zeng, Julius Wiener, Marie‐Christin Leusmann, Colin Stein, Constantin G. Daniliuc, Frank Glorius   +6 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

PLoS ONE, 2013
BackgroundThe effect of metformin, pioglitazone and sitagliptin on β-cell function in the treatment of type 2 diabetes is controversial. Therefore, we performed a systematic review and meta-analysis to obtain a better understanding in the β-cell effects ...
Jin Lu, Jiajie Zang, Huihua Li
doaj   +1 more source

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Cancer Medicine, 2020
Sitagliptin is an emerging oral hypoglycemic agent that inhibits the development of a wide variety of tumors. Current researches indicate that the abnormal activation of Yes‐associated protein (YAP) promotes the proliferation and poor prognosis of ...
Qi Wang, Pan Lu, Tao Wang, Qianqian Zheng, Yan Li, Sean X. Leng, Xin Meng, Biao Wang, Jisheng Xie, Haiyan Zhang   +9 more
doaj   +1 more source